Lantheus to present data on PET imaging agents at SNM meeting

05/19/2010 | (free registration)

Lantheus Medical Imaging said it will present initial data from a Phase II trial of its myocardial perfusion PET imaging agent, flurpiridaz F-18, at the upcoming SNM meeting. The company also will present Phase I results on its LMI1195 cardiac neuronal PET imaging agent.

View Full Article in: (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC